Key facts
- This page summarizes Stephen Basil Thomas's Form 4 filing for Climb Bio, Inc. (CLYM).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Jan 2025, 16:15.
Stephen Basil Thomas - 01 Jan 2025 Form 4 Insider Report for Climb Bio, Inc. (CLYM)
- Reporting relationship
- Director
- Issuer ticker
- CLYM
- Reported as of
- 01 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jan 2025, 16:15:05 UTC
- Prior SEC filing
- 27 Jun 2024
- Next SEC filing
- 27 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- Emily Pimblett, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephen Basil Thomas filed Form 4 for Climb Bio, Inc. (CLYM) on 03 Jan 2025.
Change
- Previous filing in this sequence was filed on 27 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CLYM
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +50,188
- Change %
- +48%
- Price
- Shares after
- 154,095
- Date
- 01 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CLYM
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -50,188
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 50,187
- Date
- 01 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 50,188
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock.
Footnote F2
Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
Footnote F3
The RSUs were granted on June 27, 2024 and will vest as to 50% of the shares on January 1, 2025, as to 25% of the shares on March 27, 2025 and as to the remaining 25% of the shares on June 27, 2025, subject to the Reporting Person's continued service.